135 related articles for article (PubMed ID: 19945743)
1. Characterization of humoral responses of ovarian cancer patients: antibody subclasses and antigenic components.
Taylor DD; Atay S; Metzinger DS; Gercel-Taylor C
Gynecol Oncol; 2010 Feb; 116(2):213-21. PubMed ID: 19945743
[TBL] [Abstract][Full Text] [Related]
2. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine.
Ye B; Skates S; Mok SC; Horick NK; Rosenberg HF; Vitonis A; Edwards D; Sluss P; Han WK; Berkowitz RS; Cramer DW
Clin Cancer Res; 2006 Jan; 12(2):432-41. PubMed ID: 16428483
[TBL] [Abstract][Full Text] [Related]
3. Humoral immune responses to cathepsin D and glucose-regulated protein 78 in ovarian cancer patients.
Chinni SR; Falchetto R; Gercel-Taylor C; Shabanowitz J; Hunt DF; Taylor DD
Clin Cancer Res; 1997 Sep; 3(9):1557-64. PubMed ID: 9815843
[TBL] [Abstract][Full Text] [Related]
4. Presence of aberrant tumor-reactive immunoglobulins in the circulation of patients with ovarian cancer.
Gerçel-Taylor C; Bazzett LB; Taylor DD
Gynecol Oncol; 2001 Apr; 81(1):71-6. PubMed ID: 11277653
[TBL] [Abstract][Full Text] [Related]
5. Shed membrane fragment-associated markers for endometrial and ovarian cancers.
Taylor DD; Lyons KS; Gerçel-Taylor C
Gynecol Oncol; 2002 Mar; 84(3):443-8. PubMed ID: 11855885
[TBL] [Abstract][Full Text] [Related]
6. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer.
Goodell V; Salazar LG; Urban N; Drescher CW; Gray H; Swensen RE; McIntosh MW; Disis ML
J Clin Oncol; 2006 Feb; 24(5):762-8. PubMed ID: 16391298
[TBL] [Abstract][Full Text] [Related]
7. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer.
Jones MB; Krutzsch H; Shu H; Zhao Y; Liotta LA; Kohn EC; Petricoin EF
Proteomics; 2002 Jan; 2(1):76-84. PubMed ID: 11788994
[TBL] [Abstract][Full Text] [Related]
8. Identification of tumor antigens that elicit a humoral immune response in breast cancer patients' sera by serological proteome analysis (SERPA).
Hamrita B; Chahed K; Kabbage M; Guillier CL; Trimeche M; Chaïeb A; Chouchane L
Clin Chim Acta; 2008 Jul; 393(2):95-102. PubMed ID: 18424265
[TBL] [Abstract][Full Text] [Related]
9. Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients.
Gagnon A; Kim JH; Schorge JO; Ye B; Liu B; Hasselblatt K; Welch WR; Bandera CA; Mok SC
Clin Cancer Res; 2008 Feb; 14(3):764-71. PubMed ID: 18245537
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor and anti-ovarian autoantibodies in women with ovarian cancer.
Barua A; Bradaric MJ; Kebede T; Espionosa S; Edassery SL; Bitterman P; Rotmensch J; Luborsky JL
Am J Reprod Immunol; 2007 Apr; 57(4):243-9. PubMed ID: 17362385
[TBL] [Abstract][Full Text] [Related]
11. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer.
Lokshin AE; Winans M; Landsittel D; Marrangoni AM; Velikokhatnaya L; Modugno F; Nolen BM; Gorelik E
Gynecol Oncol; 2006 Aug; 102(2):244-51. PubMed ID: 16434085
[TBL] [Abstract][Full Text] [Related]
12. Characterization of serum biomarkers for detection of early stage ovarian cancer.
Kozak KR; Su F; Whitelegge JP; Faull K; Reddy S; Farias-Eisner R
Proteomics; 2005 Nov; 5(17):4589-96. PubMed ID: 16237736
[TBL] [Abstract][Full Text] [Related]
13. Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer.
Taylor DD; Gercel-Taylor C; Parker LP
Gynecol Oncol; 2009 Oct; 115(1):112-120. PubMed ID: 19647308
[TBL] [Abstract][Full Text] [Related]
14. Antibody development to viral and allogeneic tumor cell-associated antigens in patients with malignant melanoma and ovarian carcinoma treated with lysates of virus-infected tumor cells.
Savage HE; Rossen RD; Hersh EM; Freedman RS; Bowen JM; Plager C
Cancer Res; 1986 Apr; 46(4 Pt 2):2127-33. PubMed ID: 3948184
[TBL] [Abstract][Full Text] [Related]
15. Epitope recognition by anti-cathepsin D autoantibodies in endometrial cancer patients.
Bosscher JR; Gerçel-Taylor C; Watkins CS; Taylor DD
Gynecol Oncol; 2001 May; 81(2):138-43. PubMed ID: 11330940
[TBL] [Abstract][Full Text] [Related]
16. [Purification and characterization of corresponding antigen recognized by monoclonal antibody 183B2 against ovarian carcinoma].
Guo HF; Feng J; Zhang H; Yao Y; Cheng HY
Zhonghua Fu Chan Ke Za Zhi; 2005 Sep; 40(9):614-8. PubMed ID: 16202318
[TBL] [Abstract][Full Text] [Related]
17. Proteomic studies of early-stage and advanced ovarian cancer patients.
Wang J; Zhang X; Ge X; Guo H; Xiong G; Zhu Y
Gynecol Oncol; 2008 Oct; 111(1):111-9. PubMed ID: 18703221
[TBL] [Abstract][Full Text] [Related]
18. Humoral immune responses against tumor-associated antigen OVA66 originally defined by serological analysis of recombinant cDNA expression libraries and its potentiality in cellular immunity.
Jin S; Wang Y; Zhang Y; Zhang HZ; Wang SJ; Tang JQ; Chen HJ; Ge HL
Cancer Sci; 2008 Aug; 99(8):1670-8. PubMed ID: 18754882
[TBL] [Abstract][Full Text] [Related]
19. Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection.
Erkanli A; Taylor DD; Dean D; Eksir F; Egger D; Geyer J; Nelson BH; Stone B; Fritsche HA; Roden RB
Cancer Res; 2006 Feb; 66(3):1792-8. PubMed ID: 16452240
[TBL] [Abstract][Full Text] [Related]
20. B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression.
Simon I; Katsaros D; Rigault de la Longrais I; Massobrio M; Scorilas A; Kim NW; Sarno MJ; Wolfert RL; Diamandis EP
Gynecol Oncol; 2007 Aug; 106(2):334-41. PubMed ID: 17498784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
